Chinese COVID-19 drugs are expected to be launched soon
- What are the symptoms of being infected with Omicron variant?
- The sleep signal from the body is actually an “alert” of brain DNA damage
- Single people are more susceptible to cancer and with higher death rate
- Omicron: Japan will close the door to businessman and international students
- Omicron variants will greatly reduce the effectiveness of COVID-19 vaccines?
- COVID-19 Omicron variant is really more terrible than Delta variant?
Chinese COVID-19 drugs are expected to be launched soon.
- COVID-19 Omicron variant is really more terrible than Delta variant?
- South Africa found “Worst so far” new COVID-19 variant: B.1.1.529
- Six EU countries suspended Moderna COVID-19 vaccine for young people
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- Scientists are Looking for people with “Natural Immunity” of COVID-19
- Why is Israel still out of control on COVID-19 even with 78% vaccination?
- WHO chief scientist: Soumya Swaminathan may face death penalty charges?
Chinese COVID-19 drugs are expected to be launched soon.
The latest news shows that China’s COVID-19 specific drugs finally have a “timetable”, and one of the antibody combination drugs is expected to be approved for conditional listing before the end of the year at the earliest.
According to statistics, there are currently six specific drugs for COVID-19 developed in China. Among them, two effective neutralizing antibody drugs BRII-196 and BRII-198 jointly developed and screened by Tsinghua University, Shenzhen Third People’s Hospital and Tengsheng Huachuang have participated in the treatment of more than 700 patients in China.
The R&D team has submitted the conditional listing application materials to the State Food and Drug Administration on October 9, and is expected to be approved for conditional listing before the end of December.
Professor Zhang Linqi of Tsinghua University: Hundreds of antibodies isolated from the blood of convalescent patients with COVID-19 have screened two antibodies with the highest activity and strong complementarity. In clinical trials conducted at home and abroad, they have shown that they can reduce severe illness and mortality by 78 % Excellent results.
At the same time, the neutralizing antibody DXP604, jointly developed by Peking University’s Xie Xiaoliang team and Danxu Biotechnology, was used as a “sympathetic drug” in Beijing Ditan Hospital when no other drugs were available. After the drug, some patients have recovered and discharged.
In addition, the new generation of androgen receptor antagonist “Prokalutamide” under development by the pioneering pharmaceutical industry has been authorized for emergency use in Paraguay. Three clinical trials conducted in Brazil initially showed that “procrudamide” can Reduce the risk of death for severely ill patients by 78%.
According to the relevant person in charge, the current research and development of effective drugs for the new coronavirus is mainly focused on three technical routes of blocking the virus from entering cells, inhibiting virus replication, and regulating the human immune system. China has already deployed these technical routes.
Chinese COVID-19 drugs are expected to be launched soon.
(source:internet, reference only)
Disclaimer of medicaltrend.org
